Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis.
Using an inhalation model of pulmonary aspergillosis, we observed modest differences in the survival rates of mice treated with granulocyte colony-stimulating factor (G-CSF) and posaconazole (POS) and those treated with POS alone. This finding is in contrast to a previous report that suggested that G-CSF had a significant antagonistic effect on the antifungal activity of POS.
Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA. andriani.patera@spcorp.com
Andriani C
AC
Patera
Frederick
F
Menzel
Craig
C
Jackson
Joan K
JK
Brieland
Judy
J
Halpern
Roberta
R
Hare
Anthony
A
Cacciapuoti
David
D
Loebenberg
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D008168:Lung / Q000382:microbiology; D008297:Male; D051379:Mice; D016019:Survival Analysis; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; D016179:Granulocyte Colony-Stimulating Factor; C101425:posaconazole